Phase I clinical trial of LGD-4033, a novel selective androgen receptor modulator (SARM)

被引：0

作者：

Meglasson, Martin D. ^{[1
]}

Kapil, Ram ^{[1
]}

Leibowitz, Mark T. ^{[2
]}

Peterkin, Joanna J. ^{[3
]}

Chen, Yanling ^{[1
]}

Lee, Kyoung-Jin ^{[1
]}

Lee, Yong-Hee ^{[1
]}

Vajda, Eric G. ^{[1
]}

机构：

[1] Ligand Pharmaceut Inc, La Jolla, CA 92037 USA

[2] CEDRA Clin Res LLC, San Antonio, TX USA

[3] Joanna J Peterkin Consulting LLC, Rancho Santa Fe, CA USA

来源：

ENDOCRINE JOURNAL | 2010年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S542 / S542

页数：1

共 50 条

[31] Combination treatment with a Selective Androgen Receptor Modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats
Vajda, E. G.
Hogue, A.
Griffiths, K. N.
Chang, W. Y.
Burnett, K.
Marschke, K.
Mais, D. E.
Pedram, B.
Shen, Y.
van Oeveren, A.
Lopez, F. J.
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S126 - S126
[32] Combination Treatment With a Selective Androgen Receptor Modulator (SARM) and a Bisphosphonate Has Additive Effects in Osteopenic Female Rats
Vajda, Eric G.
Hogue, Aimee
Griffiths, Kimberly N.
Chang, William Y.
Burnett, Kelven
Chen, Yanling
Marschke, Keith
Mais, Dale E.
Pedram, Bijan
Shen, Yixing
van Oeveren, Arjan
Zhi, Lin
Lopez, Francisco J.
Meglasson, Martin D.
JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (02) : 231 - 240
[33] Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats
Jeffrey D. Kearbey
Wenqing Gao
Ramesh Narayanan
Scott J. Fisher
Di Wu
Duane D. Miller
James T. Dalton
Pharmaceutical Research, 2007, 24 : 328 - 335
[34] Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes
Thevis, Mario
Piper, Thomas
Dib, Josef
Lagojda, Andreas
Kuehne, Dirk
Packschies, Lars
Geyer, Hans
Schaenzer, Wilhelm
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2017, 31 (14) : 1175 - 1183
[35] Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscie wasting in NSCLC
Crawford, J.
Dalton, J. T.
Hancock, M. L.
Johnston, M. A.
Steiner, M. S.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S10 - S10
[36] A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor positive triple negative breast cancer
Yuan, Yuan
Frankel, Paul
Synold, Timothy
Lee, Peter
Yost, Susan
Martinez, Norma
Tang, Aileen
Mendez, Blanca
Schmolze, Daniel
Apple, Sophia
Hurria, Arti
Waisman, James
Somlo, George
Tank, Niki
Sedrak, Mina
Mortimer, Joanne
CANCER RESEARCH, 2018, 78 (04)
[37] Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226
Wang, Feng
Liu, Xiao-qin
Li, He
Liang, Kai-ni
Miner, Jeffrey N.
Hong, Mei
Kallel, E. Adam
van Oeveren, Arjan
Zhi, Lin
Jiang, Tao
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2006, 62 : 1067 - 1071
[38] Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
Thum, Thomas
Springer, Jochen
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) : 121 - 123
[39] The forensic response after an adverse analytical finding (doping) involving a selective androgen receptor modulator (SARM) in human athlete
Kintz, Pascal
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 207
[40] The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration
Diel, P.
Friedel, A.
Geyer, H.
Kamber, M.
Laudenbach-Leschowsky, U.
Schaenzer, W.
Schleipen, B.
Thevis, M.
Vollmer, G.
Zierau, O.
TOXICOLOGY LETTERS, 2008, 177 (03) : 198 - 204

← 1 2 3 4 5 →